Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATRX_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATRX_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATRX_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATRX_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATRX_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ATRX_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATRX_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ATRX_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATRX_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATRX_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001802212 | Prostate | Tumor | peptidyl-lysine methylation | 34/3246 | 131/18723 | 8.36e-03 | 3.65e-02 | 34 |
GO:000206425 | Skin | AK | epithelial cell development | 51/1910 | 220/18723 | 1.50e-08 | 9.13e-07 | 51 |
GO:007233128 | Skin | AK | signal transduction by p53 class mediator | 41/1910 | 163/18723 | 3.41e-08 | 1.80e-06 | 41 |
GO:00165709 | Skin | AK | histone modification | 84/1910 | 463/18723 | 1.10e-07 | 4.95e-06 | 84 |
GO:004860819 | Skin | AK | reproductive structure development | 77/1910 | 424/18723 | 3.56e-07 | 1.36e-05 | 77 |
GO:006145820 | Skin | AK | reproductive system development | 77/1910 | 427/18723 | 4.76e-07 | 1.74e-05 | 77 |
GO:000632518 | Skin | AK | chromatin organization | 73/1910 | 409/18723 | 1.40e-06 | 4.26e-05 | 73 |
GO:00063384 | Skin | AK | chromatin remodeling | 51/1910 | 255/18723 | 1.95e-06 | 5.73e-05 | 51 |
GO:001063924 | Skin | AK | negative regulation of organelle organization | 64/1910 | 348/18723 | 2.19e-06 | 6.25e-05 | 64 |
GO:003304410 | Skin | AK | regulation of chromosome organization | 40/1910 | 187/18723 | 4.47e-06 | 1.07e-04 | 40 |
GO:004578716 | Skin | AK | positive regulation of cell cycle | 58/1910 | 313/18723 | 5.08e-06 | 1.19e-04 | 58 |
GO:000072320 | Skin | AK | telomere maintenance | 31/1910 | 131/18723 | 6.10e-06 | 1.39e-04 | 31 |
GO:00182058 | Skin | AK | peptidyl-lysine modification | 66/1910 | 376/18723 | 7.80e-06 | 1.72e-04 | 66 |
GO:00309006 | Skin | AK | forebrain development | 66/1910 | 379/18723 | 1.02e-05 | 2.17e-04 | 66 |
GO:000979110 | Skin | AK | post-embryonic development | 22/1910 | 80/18723 | 1.08e-05 | 2.28e-04 | 22 |
GO:003220418 | Skin | AK | regulation of telomere maintenance | 22/1910 | 80/18723 | 1.08e-05 | 2.28e-04 | 22 |
GO:00064799 | Skin | AK | protein methylation | 38/1910 | 181/18723 | 1.21e-05 | 2.46e-04 | 38 |
GO:00082139 | Skin | AK | protein alkylation | 38/1910 | 181/18723 | 1.21e-05 | 2.46e-04 | 38 |
GO:200125220 | Skin | AK | positive regulation of chromosome organization | 22/1910 | 82/18723 | 1.65e-05 | 3.16e-04 | 22 |
GO:00323927 | Skin | AK | DNA geometric change | 23/1910 | 90/18723 | 2.53e-05 | 4.54e-04 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATRX | SNV | Missense_Mutation | novel | c.200N>T | p.Ser67Phe | p.S67F | P46100 | protein_coding | deleterious(0) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ATRX | SNV | Missense_Mutation | | c.6083N>C | p.Arg2028Pro | p.R2028P | P46100 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
ATRX | SNV | Missense_Mutation | | c.2686N>C | p.Asp896His | p.D896H | P46100 | protein_coding | tolerated_low_confidence(0.2) | benign(0.347) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ATRX | SNV | Missense_Mutation | | c.3739N>C | p.Asp1247His | p.D1247H | P46100 | protein_coding | deleterious(0) | possibly_damaging(0.533) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATRX | SNV | Missense_Mutation | novel | c.6649G>A | p.Asp2217Asn | p.D2217N | P46100 | protein_coding | tolerated(0.06) | possibly_damaging(0.791) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATRX | SNV | Missense_Mutation | | c.3392G>T | p.Arg1131Ile | p.R1131I | P46100 | protein_coding | deleterious_low_confidence(0.02) | benign(0.259) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATRX | SNV | Missense_Mutation | novel | c.3161C>T | p.Ser1054Phe | p.S1054F | P46100 | protein_coding | tolerated_low_confidence(0.27) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATRX | SNV | Missense_Mutation | rs138256318 | c.2898G>T | p.Glu966Asp | p.E966D | P46100 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATRX | SNV | Missense_Mutation | novel | c.1805G>A | p.Gly602Asp | p.G602D | P46100 | protein_coding | tolerated_low_confidence(0.38) | possibly_damaging(0.69) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATRX | SNV | Missense_Mutation | novel | c.1234G>T | p.Asp412Tyr | p.D412Y | P46100 | protein_coding | tolerated(0.07) | benign(0.34) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | Gemcitabine | GEMCITABINE | 26853339 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | Radiotherapy | | 26853339 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | AZ20 | | 25593184 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | PROCARBAZINE | PROCARBAZINE | 23904111 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | Irinotecan | IRINOTECAN | 26936505 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | Topotecan | TOPOTECAN | 26936505 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | Doxorubicin | DOXORUBICIN | 26936505 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | E7449 | 2X-121 | 26513298 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | LOMUSTINE | LOMUSTINE | 23904111 |
546 | ATRX | ENZYME, CLINICALLY ACTIONABLE, DNA REPAIR | | VE-821 | | 25593184 |